NASDAQ · TSHA
Taysha Gene Therapies, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TSHA: Nov 3, 2026
Taysha Gene Therapies, Inc. Common Stock is estimated to report earnings on 11/03/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.14. The reported EPS for the same quarter last year was $-0.09.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.14 | $-0.13 | $-0.14 | 3 |
| Dec 2026 | $-0.14 | $-0.14 | $-0.14 | 2 |
| Mar 2027 | $-0.14 | $-0.14 | $-0.14 | 2 |
| Jun 2027 | $-0.15 | $-0.14 | $-0.15 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · The Motley Fool · RTTNews · NASDAQ.com- MarketBeat · Sep 7, 11:35 AM EDTThese 3 Risky Stocks Could Be Sitting on 100% UpsideWith industrials, energy, and tech stocks undergirding an S&P 500 that is hovering near all-time highs, investors looking for high-upside companies may be resigned to more speculative plays. While it's true that some long-established firms have posted surprising rallies in recen
- The Motley Fool · Aug 18, 7:13 PM EDTTaysha Gene Therapies (TSHA) Q2 2026 Earnings Call@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 11, 9:04 PM EDTTaysha Gene Therapies Q2 Earnings Call HighlightsNeurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"Taysha Gene Therapies (NASDAQ:TSHA) said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential biologics license
- The Motley Fool · Jul 12, 2:15 PM EDTTaysha's R&D Chief Sold $1.2 Million in Stock After a 149% RunThe transaction involved the sale of 200,000 shares at a weighted average price of $6.24 per share on July 10.
- RTTNews · Jun 25, 2:07 AM EDTTaysha Gene Therapies Prices Approx. $200 Mln Offering Of Shares And Warrants; Stock Down(RTTNews) – Taysha Gene Therapies, Inc. (TSHA), a clinical-stage biotechnology company focused on developing gene therapies, priced the offering of 32.50 million shares of its common stock at a price of $6 per share and pre-funded warrants to purchase 0.833 million shares of its
- The Motley Fool · May 7, 11:29 AM EDTTaysha (TSHA) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Apr 28, 9:23 AM EDTTaysha To Present Preclinical Data On TSHA-102 Gene Therapy In Treatment Of Rett Syndrome(RTTNews) – Taysha Gene Therapies Inc. (TSHA), a clinical-stage biotechnology company, said preclinical in vitro data on TSHA-102, a scAAV9 gene therapy developed for treating Rett syndrome will be presented at the annual meeting of the American Society of Gene and Cell Therapy (
- The Motley Fool · Mar 19, 10:20 AM EDTTaysha (TSHA) Q4 2025 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- NASDAQ.com · Mar 18, 4:00 PM EDTPre-Market Earnings Report for March 19, 2026 : ACN, BABA, DRI, SIG, LUNR, AVAH, TSHA, CSIQ, ARCO, TRC, LE, TITNThe following companies are expected to report earnings prior to market open on 03/19/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Accenture plc (ACN)is reporting for the quarter ending February 28, 2026. The information technology services com
- BNK Invest · Feb 17, 12:31 PM ESTCommit To Buy Taysha Gene Therapies At $2.50, Earn 16.8% Annualized Using OptionsInvestors eyeing a purchase of Taysha Gene Therapies Inc (Symbol: TSHA) shares, but tentative about paying the going market price of $4.61/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in part
- BNK Invest · Nov 11, 11:56 AM ESTCommit To Purchase Taysha Gene Therapies At $2.50, Earn 24% Using OptionsInvestors considering a purchase of Taysha Gene Therapies Inc (Symbol: TSHA) shares, but cautious about paying the going market price of $3.96/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in
- Fintel · Nov 5, 7:11 PM ESTChardan Capital Maintains Taysha Gene Therapies (TSHA) Buy RecommendationFintel reports that on November 5, 2025, Chardan Capital maintained coverage of Taysha Gene Therapies (NasdaqGS:TSHA) with a Buy recommendation. Analyst Price Forecast Suggests 147.88% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Taysha Gene Therapies, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.